Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-Positive Early Breast Cancer × Trastuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 622 Stomach Neoplasms 75 Neoplasm Metastasis 59 Neoplasms 39 HER2-positive Breast Cancer 33 Breast Neoplasms, Male 30 Colorectal Neoplasms 28 Brain Neoplasms 25 Carcinoma, Non-Small-Cell Lung 21 Inflammatory Breast Neoplasms 20 Esophageal Neoplasms 20 Pancreatic Neoplasms 13 Triple Negative Breast Neoplasms 12 Lung Neoplasms 11 Endometrial Neoplasms 11 Ovarian Neoplasms 10 Colonic Neoplasms 10 Urinary Bladder Neoplasms 9 Rectal Neoplasms 9 Prostatic Neoplasms 9 Cardiotoxicity 8 Adenocarcinoma 8 Salivary Gland Neoplasms 7 Gallbladder Neoplasms 7 Breast Diseases 7 Biliary Tract Neoplasms 7 Adenocarcinoma Of Esophagus 7 Uterine Cervical Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 6 Sarcoma 6

Interventions

pertuzumab 1 Trastuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03674112 2024-01-02

PHranceSCa

Hoffmann-La Roche

Phase 2 Completed

160 enrolled 53 charts

HER2-Positive Early Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡